SCHEDULE 13G/A: BlackRock Amends Stake in Travere Therapeutics, Discloses 9.4% Ownership
Beneficial Ownership Disclosure
BlackRock, Inc. has filed an amended Schedule 13G, revealing a 9.4% beneficial ownership stake in Travere Therapeutics, Inc. as of December 31, 2024.
Summary
- BlackRock, Inc. filed Amendment No. 10 to its Schedule 13G regarding beneficial ownership of common stock in Travere Therapeutics, Inc.
- As of December 31, 2024, BlackRock beneficially owns an aggregate of 8,018,292 shares of Travere Therapeutics, Inc. common stock.
- This ownership represents 9.4% of the total class of securities outstanding.
- BlackRock holds sole voting power over 7,771,441 shares and sole dispositive power over 8,018,292 shares.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: Neutral. This document is a factual disclosure of beneficial ownership by a large institutional investor and does not contain information that would indicate a positive or negative sentiment regarding the issuer's performance or prospects.
Positives
- BlackRock, a prominent institutional investor, maintains a significant 9.4% stake in Travere Therapeutics, Inc., which may be interpreted as a vote of confidence in the company.
- The filing explicitly states that BlackRock's holdings are for ordinary course of business and not for control, indicating a passive investment approach.
Future Outlook
This document is a beneficial ownership disclosure and does not contain forward-looking statements or guidance regarding the issuer's future performance or outlook.
Management Comments
- "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."
Industry Context
This filing is a routine disclosure by BlackRock, a major global asset manager, detailing its passive investment stake in Travere Therapeutics, Inc., a biotechnology company. It reflects BlackRock's ongoing portfolio management activities rather than a specific strategic move related to broader industry trends or competitors.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, which may be viewed as a signal of confidence from a major investor.
- Management: Awareness of a large, passive institutional holder in the company's stock.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Date of previous Power of Attorney, which is now revoked. |
| 2024-12-31 | Date of event which requires filing of this statement (ownership snapshot date). |
| 2025-01-21 | Date of execution of the new Power of Attorney for BlackRock, Inc. |
| 2025-02-05 | Date of signing the Schedule 13G filing. |
Keywords
Travere Therapeutics, BlackRock, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, TRTX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.